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In this Special Issue we bring together papers demonstrating the need for both detailed genomic
and phenotypic studies to aid our scientific and clinical understanding of neurogenetic disorders.
Genomic techniques such as genome and exome sequencing are vital tools for diagnosing rare
neurogenetic disorders and identifying novel causal genes [1,2]. In this Special Issue, Gardner and
colleagues [3] utilise genomic techniques to identify a series of individuals with brain malformations
due to the recurrent TUBA1A p.Arg2His variant. This paper also describes the detailed phenotyping
required to aid in the interpretation of novel genomic variants. Variants in GBA1, the gene causing
Gaucher Disease (GD), are associated with an increased risk of Parkinson’s Disease (PD) [4,5].
Gatto and colleagues review this important area and describe how simple clinical observations
helped begin the identification of this important risk factor for PD [6]. Genomic techniques are crucial
for the diagnosis of neurogenetic disorders [7]. Garcia and Bustos [8] review the impact of such
techniques for both the diagnosis of neurogenetic diseases and increasing our scientific understanding
of these disorders. It is only through the co-development of both novel genomic and phenotypic
assessments that we will be able to fully understand the pathogenesis of neurogenetic disorders and
identify novel treatments.
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